Patent US4330620A successfully refreshed from Google Patents.
US4330620A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and reagent for the determination of creatine kinase MB
Assignee: Roche Diagnostics GmbH
•
Filing: 1980-02-28
•
Granted: 1982-05-18
•
Expires: 2000-02-28
Abstract
Abstract A method for the determination of creatine kinase-MB in serum by immunological exclusion of sub-unit M and measurement of the sub-unit B for the determination of creatine kinase, the improvement comprising, for the purpose of excluding the sub-unit M, adding to the reaction mixture comprising determination reagents and the creatine kinase-containing sample, monovalent fragments obtained from antibodies against the sub-unit M by proteolytic cleavage under reducing conditions.
Inventors
- 👤 Wolfgang Gruber
- 👤 Helmut Lenz
- 👤 Siegfried Looser
- 👤 Hans-Ralf Linke
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 12:15
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/48; C12Q1/50; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/70; Y; Y10; Y10S; Y10S435/00; Y10S435/962; Y10S435/968
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
67 words
In a method for the determination of creatine kinase-MB in serum sample of the type comprising immunologically neutralizing the sub-unit M in the sample with an antibody, and then measuring for the enzymatic activity of the sub-unit B of creatine kinase, the improvement comprising neutralizing the sub-unit M with monovalent antibody fragments prepared by proteolytic cleavage under reducing conditions of antibodies which completely inhibit the isoenzyme CK-MM.
Claim 2
Dependent Claim
67 words
In a method for the determination of creatine kinase-MB in serum sample of the type comprising immunologically neutralizing the sub-unit M in the sample with an antibody, and then measuring for the enzymatic activity of the sub-unit B of creatine kinase, the improvement comprising neutralizing the sub-unit M with monovalent antibody fragments prepared by proteolytic cleavage under reducing conditions of antibodies which completely inhibit the isoenzyme CK-MM.
Claim 3
Dependent Claim
31 words
The method as claimed in claim 1 wherein said monovalent fragments are obtained from antibodies which inhibit the hybrid enzyme CK-MB to more than 55% and completely inhibit the isoenzyme CK-MM.
Claim 4
Dependent Claim
26 words
The method as claimed in claim 2 wherein the monovalent fragments are obtained from antibodies which inhibit the hybrid enzyme CK-MB to from 60 to 90%.
Claim 5
Dependent Claim
25 words
The method as claimed in claim 1 wherein, from said monovalent fragments, the residual complete antibodies and the crystalline fragments F c have been separated.
Claim 6
Dependent Claim
17 words
The method as claimed in claim 1 wherein in said monovalent fragments the SH groups are alkylated.
Claim 7
Dependent Claim
19 words
The method as claimed in claim 5 wherein said monovalent fragments are alkylated with iodine acetamine or iodine acetate.
Claim 8
Dependent Claim
26 words
The method as claimed in claim 1 wherein the sub-unit B is determined by the luciferin-luciferase reaction and the emitted amount of light is measured kinetically.
Claim 9
Dependent Claim
62 words
In a reagent for the determination of creatine kinase MB comprising a reagent system for the enzymatic determination of creatine kinase MB and means for the immunological neutralization of sub-unit M of the creatine kinase MB wherein the improvement comprises using as the means a monovalent antibody fragments prepared by proteolytic cleavage under reducing conditions of antibodies which completely inhibit isoenzyme CK-MM.
Claim 10
Dependent Claim
62 words
In a reagent for the determination of creatine kinase MB comprising a reagent system for the enzymatic determination of creatine kinase MB and means for the immunological neutralization of sub-unit M of the creatine kinase MB wherein the improvement comprises using as the means a monovalent antibody fragments prepared by proteolytic cleavage under reducing conditions of antibodies which completely inhibit isoenzyme CK-MM.
Claim 11
Dependent Claim
31 words
The reagent as claimed in claim 8 wherein said monovalent fragments are obtained from antibodies which inhibit the hybrid enzyme CK-MB to more than 55% and completely inhibit the isoenzyme CK-MM.
Claim 12
Dependent Claim
26 words
The reagent as claimed in claim 9 wherein the monovalent fragments are obtained from antibodies which inhibit the hybrid enzyme CK-MB to from 60 to 90%.
Claim 13
Dependent Claim
25 words
The reagent as claimed in claim 8 wherein, from said monovalent fragments, the residual complete antibodies and the crystalline fragments F c have been separated.
Claim 14
Dependent Claim
17 words
The reagent as claimed in claim 8 wherein, in said monovalent fragments, the SH groups are alkylated.
Claim 15
Dependent Claim
19 words
The reagent as claimed in claim 12 wherein said monovalent fragments are alkylated with iodine acetamine or iodine acetate.
Claim 16
Dependent Claim
30 words
The reagent as claimed in claim 8 wherein said system for the determination of creatine kinase-MB is the luciferin-luciferase system providing for kinetic measurement of the emitted amount of light.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-05-17 | 1985-11-16 | 1986-05-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-05-17 | 1989-11-16 | 1990-05-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-05-17 | 1993-11-16 | 1994-05-18 | $7700.00 | Window Closed / Lapsed |